Welcome to our dedicated page for PHIBRO ANIMAL HEALTH SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PHIBRO ANIMAL HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PHIBRO ANIMAL HEALTH's regulatory disclosures and financial reporting.
Phibro Animal Health Corporation (PAHC) reported strong results for the fourth quarter and fiscal year ended June 30, 2026 and issued financial guidance for fiscal 2027. For the quarter, net sales were $396.7 million, up 5%, with net income of $21.7 million, up 26%, and adjusted EBITDA of $64.2 million, up 29% versus a year earlier.
For fiscal 2026, net sales were $1,518.1 million, up 17%, driven mainly by a 21% increase in Animal Health revenue to $1,162.2 million. Net income rose to $99.7 million from $48.3 million, while adjusted EBITDA increased 39% to $255.0 million and adjusted diluted EPS rose 48% to $3.22. Gross margin expanded to 33.8% from 30.9%, reflecting higher volume, favorable mix and pricing.
The company highlighted completion of its three‑year “Phibro Forward” transformation program and announced the planned closure of its Chicago Heights, Illinois manufacturing facility, expected to cease production in summer 2027 and affecting approximately 100 employees, as part of a strategic network consolidation. Total debt stood at $737.9 million. Fiscal 2027 guidance assumes minimal sales of virginiamycin in Brazil and excludes potential non-cash and one-time charges from the Chicago Heights closure and any foreign exchange gains or losses.
Phibro Animal Health Corporation (PAHC) reports strong growth for the year ended June 30, 2026 as a global animal health and mineral nutrition company. Total net sales were $1,518 million, up from $1,296 million in 2025 and $1,018 million in 2024, with Animal Health contributing $1,162 million.
Growth was driven largely by the October 2024 acquisition of Zoetis’s medicated feed additive portfolio for approximately $297.5 million, whose products generated $407.6 million of 2023 revenue and contributed $358.2 million and $208.2 million to PAHC’s 2026 and 2025 net sales. Adjusted EBITDA rose to $255 million from $184 million in 2025.
Sales increased across species and regions, with the United States accounting for $877 million of net sales and international markets providing 54% of Animal Health revenue. The company discloses significant regulatory and policy scrutiny of certain antibacterials (including carbadox and virginiamycin) and plans to close its Chicago Heights manufacturing facility as it consolidates its plant network.
Rodriguez Patrick reported acquisition or exercise transactions in this Form 4 filing.
Phibro Animal Health Corp reported that Patrick Rodriguez, VP Finance and Treasurer, received a grant of 1,503 restricted stock units (RSUs) representing Class A Common Stock. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to his continued employment, and his reported direct holdings after the award are 1,503 shares.
David Glenn reported acquisition or exercise transactions in this Form 4 filing.
PHIBRO ANIMAL HEALTH CORP reported that Chief Financial Officer David Glenn received an award of 3,334 shares of Class A Common Stock in the form of restricted stock units. The award was recorded at a per-share price of $0.00 as a grant, not a market purchase.
The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, contingent on his continued employment through each vesting date. Following this award, Glenn’s directly held Class A Common Stock position is reported as 54,811 shares.
Miller Larry Lee reported acquisition or exercise transactions in this Form 4 filing.
Phibro Animal Health Corp reported that Chief Operating Officer Larry Lee Miller received a grant of 3,522 restricted stock units (RSUs) representing Class A Common Stock on August 6, 2026. These RSUs vest in three substantially equal installments on the first three anniversaries of August 1, 2026, contingent on his continued employment. Following this award, Miller directly holds 38,071 shares of Class A Common Stock, including the RSUs.
BENDHEIM Jonathan reported acquisition or exercise transactions in this Form 4 filing.
PHIBRO ANIMAL HEALTH CORP reported that director Jonathan Bendheim received a grant of 2,716 restricted stock units (RSUs), each representing a contingent right to receive one share of Class A Common Stock. Following this award, his directly held Class A Common Stock position is 5,984 shares.
The RSUs are scheduled to vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to his continued employment through each applicable vesting date.
Weinstein Judith reported acquisition or exercise transactions in this Form 4 filing.
Phibro Animal Health Corp reported an equity compensation award to senior vice president and general counsel Judith Weinstein. She received 2,478 restricted stock units, each representing one share of Class A Common Stock, increasing her direct holdings to 5,453 shares. The RSUs vest in substantially equal installments over three years starting on August 1, 2026, conditioned on continued employment through each vesting date.
BENDHEIM JACK reported acquisition or exercise transactions in this Form 4 filing.
Phibro Animal Health Corp reported that Executive Chairman and 10% owner Jack Bendheim received a grant of 12,103 restricted stock units (RSUs), each representing one share of Class A Common Stock. These RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to his continued employment. Following the award, Bendheim directly holds 26,640 Class A shares and is also reported as having shared voting and investment power over 56,152 Class A shares held by BFI Co., LLC, while disclaiming beneficial ownership beyond his pecuniary interest.
Escudero Lisa Ann reported acquisition or exercise transactions in this Form 4 filing.
PHIBRO ANIMAL HEALTH CORP Senior Vice President of Human Resources Lisa Ann Escudero received a grant of 1,547 restricted stock units (RSUs) of Class A Common Stock on 2026-08-06. The RSUs vest in three substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to continued employment. Following this award, Escudero directly holds 3,434 shares (or share-equivalent RSUs) of Class A Common Stock.
PHIBRO ANIMAL HEALTH CORP reported an equity compensation grant to President and CEO Daniel M. Bendheim. He acquired 11,699 restricted stock units (RSUs), each representing a contingent right to receive one share of Class A Common Stock. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2026, subject to his continued employment. Following this award, Bendheim directly holds 15,177 shares of Class A Common Stock, including the RSUs.